Paul Munson

Dr. Paul Munson


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
PMPaul Munson
Paul Munson
JAJuraj Adamik
Juraj Adamik
FHFelix J. Hartmann
Felix J. Hartmann
PFPatricia M. B. Favaro
Patricia M. B. Favaro
DHDaniel Ho
Daniel Ho
LBLisa H. Butterfield
Lisa H. Butterfield
α-Fetoprotein (AFP) is expressed by stem-like and poor outcome hepatocellular cancer tumors and is a clinical tumor biomarker. AFP has been demonstrated to inhibit dendritic cell (DC) differentiation and maturation and to block oxidative phosphorylation. To identify the critical metabolic pathways leading to human DC functional suppression, here, we used two recently described single-cell profiling methods, scMEP (single-cell metabolic profiling) and SCENITH (single-cell energetic metabolism by profiling translation inhibition). Glycolytic capacity and glucose dependence of DCs were significantly increased by tumor-derived, but not normal cord blood–derived, AFP, leading to increased glucose uptake and lactate secretion. Key molecules in the electron transport chain in particular were regulated by tumor-derived AFP. These metabolic changes occurred at mRNA and protein levels, with negative impact on DC stimulatory capacity. Tumor-derived AFP bound significantly more polyunsaturated fatty acids (PUFA) than cord blood–derived AFP. PUFAs bound to AFP increased metabolic skewing and promoted DC functional suppression. PUFAs inhibited DC differentiation in vitro, and ω-6 PUFAs conferred potent immunoregulation when bound to tumor-derived AFP. Together, these findings provide mechanistic insights into how AFP antagonizes the innate immune response to limit antitumor immunity. Significance: α-Fetoprotein (AFP) is a secreted tumor protein and biomarker with impact on immunity. Fatty acid–bound AFP promotes immune suppression by skewing human dendritic cell metabolism toward glycolysis and reduced immune stimulation.

6 April 2022 in Expert Review of Vaccines
Verified
Journal Article
Closed access
PMPaul Munson
Paul Munson
Introduction: Antiretroviral therapy (ART) reduces HIV replication to undetectable levels and prevents AIDS but cannot cure the infection, and discontinuing ART results in viral rebound. Therefore, a primary goal of HIV therapeutic vaccine research is to induce potent HIV-specific immunity that could control viremia without ART, a so-called “functional cure” that eliminates the need for lifelong ART. DNA vaccines have several features that make them an attractive modality for an HIV therapeutic vaccine: they are easy to manufacture, induce T-cell and antibody responses without anti-vector immunity, and do not involve ex vivo manipulations of patient cells. Areas covered: This review covers the progress in developing therapeutic HIV DNA vaccines, emphasizing delivery innovations to enhance vaccine immunogenicity. A central theme is a transition from needle injection delivery to the muscle towards using more sophisticated devices to target the skin and/or increasing transfection efficiency. Expert opinion: There are multiple barriers to an effective therapeutic HIV DNA vaccine. While variables such as delivery, adjuvants, and immunogen design have been extensively explored, combining DNA vaccines with complementary approaches is underdeveloped. Complementary approaches include co-administration with latency reversal agents, immune checkpoint blockade, and targeting conserved fitness-constrained portions of the virus.

24 November 2025
Verified
Other
Open access
PMPaul Munson
Paul Munson
JAJuraj Adamik
Juraj Adamik
FHFelix J. Hartmann
Felix J. Hartmann
PFPatricia M.B. Favaro
Patricia M.B. Favaro
DHDaniel Ho
Daniel Ho
LBLisa H. Butterfield
Lisa H. Butterfield
α-Fetoprotein (AFP) is expressed by stem-like and poor outcome hepatocellular cancer tumors and is a clinical tumor biomarker. AFP has been demonstrated to inhibit dendritic cell (DC) differentiation and maturation and to block oxidative phosphorylation. To identify the critical metabolic pathways leading to human DC functional suppression, here, we used two recently described single-cell profiling methods, scMEP (single-cell metabolic profiling) and SCENITH (single-cell energetic metabolism by profiling translation inhibition). Glycolytic capacity and glucose dependence of DCs were significantly increased by tumor-derived, but not normal cord blood–derived, AFP, leading to increased glucose uptake and lactate secretion. Key molecules in the electron transport chain in particular were regulated by tumor-derived AFP. These metabolic changes occurred at mRNA and protein levels, with negative impact on DC stimulatory capacity. Tumor-derived AFP bound significantly more polyunsaturated fatty acids (PUFA) than cord blood–derived AFP. PUFAs bound to AFP increased metabolic skewing and promoted DC functional suppression. PUFAs inhibited DC differentiation in vitro, and ω-6 PUFAs conferred potent immunoregulation when bound to tumor-derived AFP. Together, these findings provide mechanistic insights into how AFP antagonizes the innate immune response to limit antitumor immunity.Significance:α-Fetoprotein (AFP) is a secreted tumor protein and biomarker with impact on immunity. Fatty acid–bound AFP promotes immune suppression by skewing human dendritic cell metabolism toward glycolysis and reduced immune stimulation.

2 May 2023
Verified
Other
Open access
PDF file
PMPaul Munson
Paul Munson
JAJuraj Adamik
Juraj Adamik
FHFelix J. Hartmann
Felix J. Hartmann
PFPatricia M.B. Favaro
Patricia M.B. Favaro
DHDaniel Ho
Daniel Ho
LBLisa H. Butterfield
Lisa H. Butterfield
Supplementary Figures, Table, Supplementary Tables

24 November 2025
Verified
Other
Open access
PMPaul Munson
Paul Munson
JAJuraj Adamik
Juraj Adamik
FHFelix J. Hartmann
Felix J. Hartmann
PFPatricia M.B. Favaro
Patricia M.B. Favaro
DHDaniel Ho
Daniel Ho
LBLisa H. Butterfield
Lisa H. Butterfield
Supplementary Figures, Table, Supplementary Tables

16 September 2024
Verified
Other
Open access
PDF file
PMPaul Munson
Paul Munson
JAJuraj Adamik
Juraj Adamik
FHFelix J. Hartmann
Felix J. Hartmann
PFPatricia M. B. Favaro
Patricia M. B. Favaro
DHDaniel Ho
Daniel Ho
LBLisa H. Butterfield
Lisa H. Butterfield
Supplementary Figures, Table, Supplementary Tables